LEXINGTON, Mass., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company developing novel drug candidates for the treatment of human cancers, today announced that the company's management team will host an investor and analyst day to highlight Curis' proprietary research and development programs on Thursday, October 3, 2013, from 8:00 a.m. to 11:00 a.m. EDT at The New York Palace Hotel in New York City.
Investigators and Curis' senior management will provide clinical overviews and development plans for Curis' two key proprietary cancer programs, an antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427, and a dual target phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitor, CUDC-907. Company management will also provide a corporate overview and update on partnered programs involving Erivedge® and Debio 0932.
A live webcast and accompanying slide presentation can be accessed by visiting the Investor Relations section of Curis' website at http://investors.curis.com/events.cfm.
About Curis, Inc.
Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information:
Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
617-503-6605
mmohindru@curis.com
Michael P. Gray
Chief Financial and Chief Business Officer
Curis, Inc.
617-503-6632
mgray@curis.com
